Clair Health Raises $11.6M to Build the First Continuous, Noninvasive Hormone-Tracking Wearable
Led by Khosla Ventures — with angels including Anne Wojcicki — the Stanford-founded startup packs 10 biosensors into a wrist wearable targeting perimenopause, cycle irregularity, and the gaps period-tracking apps can't reach.
Clair Health, founded by Stanford graduates Jenny Duan, 22, and Abhinav Agarwal, has raised $11.6 million led by Khosla Ventures to build a wrist wearable that continuously and noninvasively tracks hormones including estrogen and progesterone. The device is slated to launch in November 2026, priced at $369 plus a $9.99 monthly subscription, with preorders and a beta program open now.
The technical claim is bold: continuous hormone monitoring without needles, using an array of 10 biosensors including a novel biomagnetic sensor. AI voice-based onboarding analyzes biomarkers alongside the sensor data, and data partnerships give the company access to millions of electronic health records for model development.
The gap it targets
Women's health wearables have largely meant period-tracking apps and temperature-based cycle prediction. Clair aims at what those can't see: perimenopause, cycle irregularity, inflammation, and energy patterns — conditions and questions that hinge on actual hormone levels, which today require lab draws to measure.
The investor roster — Khosla leading, joined by a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and angels including Wojcicki — signals continued VC appetite for women's health hardware beyond software trackers. The physiology is hard and the validation bar will be high; if the sensors deliver, the category shifts from tracking cycles to measuring the biology underneath them.
Reporting: TechCrunch, June 17, 2026.
Source
Original reporting: TechCrunch ↗